J. Kaitlin Morrison

554 total citations
17 papers, 380 citations indexed

About

J. Kaitlin Morrison is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, J. Kaitlin Morrison has authored 17 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 5 papers in Molecular Biology. Recurrent topics in J. Kaitlin Morrison's work include CAR-T cell therapy research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and CRISPR and Genetic Engineering (4 papers). J. Kaitlin Morrison is often cited by papers focused on CAR-T cell therapy research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and CRISPR and Genetic Engineering (4 papers). J. Kaitlin Morrison collaborates with scholars based in United States and Germany. J. Kaitlin Morrison's co-authors include Ethel Cesarman, Jia Ruan, Scott Ely, Ann S. LaCasce, John P. Leonard, Morton Coleman, Peter Martin, Rebecca Elstrom, Shing M. Lee and Julie M. Vose and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

J. Kaitlin Morrison

16 papers receiving 379 citations

Peers

Countries citing papers authored by J. Kaitlin Morrison

Since Specialization

Citations

This map shows the geographic impact of J. Kaitlin Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Kaitlin Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Kaitlin Morrison more than expected).

Fields of papers citing papers by J. Kaitlin Morrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Kaitlin Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Kaitlin Morrison. The network helps show where J. Kaitlin Morrison may publish in the future.

Co-authorship network of co-authors of J. Kaitlin Morrison

This figure shows the co-authorship network connecting the top 25 collaborators of J. Kaitlin Morrison. A scholar is included among the top collaborators of J. Kaitlin Morrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Kaitlin Morrison. J. Kaitlin Morrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30+ Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin 2024 ·Blood ·(unknown), Catherine Cheng, (unknown), (unknown), John A. West, J. Kaitlin Morrison, Faith Brianne Buchanan, (unknown), (unknown), Kimberly A. Kasow, Anastasia Ivanova, Edith V. Bowers, Jonathan S. Serody, Barbara Savoldo, Gianpietro Dotti, Natalie S. Grover, Anne Beaven	1
2	CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma 2024 ·Blood ·Natalie S. Grover, (unknown), Anastasia Ivanova, Anne Beaven, Christopher Dittus, Catherine Cheng, (unknown), (unknown), Faith Brianne Buchanan, (unknown), (unknown), John A. West, J. Kaitlin Morrison, Paul M. Armistead, Kimberly A. Kasow, Jonathan S. Serody, Gianpietro Dotti, Barbara Savoldo	0
3	Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas 2023 ·Journal for ImmunoTherapy of Cancer ·Nicholas Tschernia, Hillary Heiling, Allison M. Deal, Catherine Cheng, (unknown), (unknown), J. Kaitlin Morrison, Christopher Dittus, Gianpietro Dotti, Anne Beaven, Jonathan S. Serody, William A. Wood, Barbara Savoldo, Natalie S. Grover	8
4	CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/ Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma 2022 ·Transplantation and Cellular Therapy ·Natalie S. Grover, Anastasia Ivanova, Dominic Moore, Catherine Cheng, (unknown), John B. West, (unknown), J. Kaitlin Morrison, Faith Brianne Buchanan, Edith V. Bowers, Christopher Dittus, Anne Beaven, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo	2
5	Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma 2022 ·Blood ·Timothy Voorhees, Anne Beaven, Christopher Dittus, George Hucks, J. Kaitlin Morrison, Catherine Cheng, (unknown), Steven I. Park, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo, Natalie S. Grover	4
6	Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates 2022 ·Blood ·Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubiños, Natalie S. Grover, Paul M. Armistead, James M. Coghill, Katarzyna Jamieson, Robert S. Hagan, J. Kaitlin Morrison, Faith Brianne Buchanan, Catherine Cheng, Anastasia Ivanova, (unknown), John A. West, (unknown), Jonathan S. Serody, Gianpietro Dotti	1
7	CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma 2021 ·Blood ·Natalie S. Grover, Anastasia Ivanova, Dominic T. Moore, Catherine Cheng, (unknown), John A. West, (unknown), J. Kaitlin Morrison, Faith Brianne Buchanan, Edith V. Bowers, Christopher Dittus, Anne Beaven, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo	28
8	CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients 2021 ·Blood ·George Hucks, Barbara Savoldo, Gianpietro Dotti, Catherine Cheng, (unknown), Kimberly A. Kasow, (unknown), Arpita Patel, (unknown), Natalie S. Grover, J. Kaitlin Morrison, Anne Beaven, Marcie Riches, Thomas C. Shea, Jonathan S. Serody	6
9	Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma 2021 ·Blood Advances ·Timothy Voorhees, (unknown), Jorge D. Oldan, George Hucks, Amir H. Khandani, Christopher Dittus, Jennifer K. Smith, J. Kaitlin Morrison, Catherine Cheng, Anastasia Ivanova, Steven Park, Thomas C. Shea, Anne Beaven, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo, Natalie S. Grover	36
10	Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL) 2020 ·Blood ·Matthew C. Foster, Philip Roehrs, George Hucks, Natalie S. Grover, Paul M. Armistead, Katarzyna Jamieson, Faith Brianne Buchanan, J. Kaitlin Morrison, (unknown), Catherine Cheng, Jonathan S. Serody, Gianpietro Dotti, Barbara Savoldo	4
11	Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma 2019 ·Blood ·Timothy Voorhees, Natalie S. Grover, Anne Beaven, Steven Park, J. Kaitlin Morrison, Catherine Cheng, (unknown), Gianpietro Dotti, Barbara Savoldo, Jonathan S. Serody	6
12	Spatial and temporal translational control of germ cell mRNAs mediated by the eIF4E isoform IFE-1 2015 ·Journal of Cell Science ·(unknown), Melissa A. Henderson, J. Kaitlin Morrison, (unknown), Brett D. Keiper	13
13	Induction of cap-independent BiP (hsp-3) and Bcl-2 (ced-9) translation in response to eIF4G (IFG-1) depletion inC. elegans 2014 ·PubMed ·J. Kaitlin Morrison, (unknown), Melissa A. Henderson, Enhui Hao, Brett D. Keiper	10
14	POU1F1-Mediated Activation of hGH-N by Deoxyribonuclease I Hypersensitive Site II of the Human Growth Hormone Locus Control Region 2011 ·Journal of Molecular Biology ·(unknown), (unknown), J. Kaitlin Morrison, Andrew Franklin, Brian M. Shewchuk	7
15	Cap-Independent Translation Promotes C. elegans Germ Cell Apoptosis through Apaf-1/CED-4 in a Caspase-Dependent Mechanism 2011 ·PLoS ONE ·(unknown), (unknown), J. Kaitlin Morrison, Enhui Hao, Brett D. Keiper	17
16	Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup. 2010 ·Blood ·Peter Martin, Morton Coleman, Richard R. Furman, Shankar Vallabhajosula, (unknown), (unknown), J. Kaitlin Morrison, Rebecca Elstrom, Jia Ruan, Stanley J. Goldsmith, John P. Leonard	2
17	Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma 2010 ·Journal of Clinical Oncology ·Jia Ruan, Peter Martin, Richard R. Furman, Shing M. Lee, Ken Cheung, Julie M. Vose, Ann S. LaCasce, J. Kaitlin Morrison, Rebecca Elstrom, Scott Ely, Amy Chadburn, Ethel Cesarman, Morton Coleman, John P. Leonard	235

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact